Liso-cel achieved high response rates in patients with R/R mantle cell lymphoma treated in routine clinical practice

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

EHA 2025

Leukemia

Blinatumomab led to high remission and MRD negativity rates in routine clinical practice for adult Ph-negative B-cell ALL

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

ASH 2025

Lymphoma

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

CHICAGO 2026

Lymphoma

Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL

Lymphoma

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

Br J Haematol

O'Reilly MA, Wilson W, Maybury B, Kuhnl A, Roddie C, Uttenthal B, Johnson R, Alajangi R, Creasey T, Abdulgawad A, Arias CG, Iyengar S, Ferguson G, Panopoulou K, Delaney A, Pryce A, Rubio L, Jones C, Lambert J, Gupta S, Mathew A, Kasivisvanathan S, Awofisayo O, Hanmantgad S, Collins GP, Besley C, Seymour F, Sanderson R, Chaganti S

doi: 10.1111/bjh.70357

Lymphoma

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial

Leukemia

Khouja M, Genuardi E, Ferrero S, Laqua A, Alessandria B, Verhagen OJHM, Homburg CHE, Sanz RG, Medina Herrera A, van der Velden VHJ, da Silva MG, Gameiro P, Doorduijn J, Giné E, Visco C, Brüggemann M, Baldus CD, Ladetto M, Schmidt C, Dreyling M, Jiang L, Hoster E, Darzentas N, Pal K, Chitadze G, Stewart JP, Gonzalez D, Pott C, European MCL Network

doi: 10.1038/s41375-025-02787-0

EHA/ICML 2025

Lymphoma

Expanding the Curative Potential of CAR T-Cell Therapy

Multiple Myeloma (MM)

Related content

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Blinatumomab led to high remission and MRD negativity rates in routine clinical practice for adult Ph-negative B-cell ALL

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial

Expanding the Curative Potential of CAR T-Cell Therapy

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM